HUTCHMED (China) (HMDCF) Income towards Parent Company (2015 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Income towards Parent Company came in at -$235.7 million in Q4 2021, down 238.27% quarter-over-quarter from $170.5 million in Q3 2021.
Analysis
HUTCHMED (China) (HMDCF) Income towards Parent Company (2015 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Income towards Parent Company for 6 consecutive years, with -$235.7 million the latest figure, recorded in Q4 2021.
- On a quarterly basis, Income towards Parent Company changed N/A year-over-year to -$235.7 million in Q4 2021; TTM through Dec 2021 was -$203.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $562.3 million, up 9140.77% from the prior year.
- Income towards Parent Company was -$235.7 million for Q4 2021 at HUTCHMED (China), down from $170.5 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $170.5 million in Q3 2021 and troughed at -$235.7 million in Q4 2021.
- A 4-year average of -$23.8 million and a median of -$32.3 million in 2019 frame the typical range for Income towards Parent Company.
- The widest YoY moves for Income towards Parent Company: up 250.63% in 2019, down 367.87% in 2019.
- Over 4 years, Income towards Parent Company stood at $22.1 million in 2018, then plunged by 270.87% to -$37.8 million in 2019, then slipped by 17.28% to -$44.3 million in 2020, then slumped by 432.37% to -$235.7 million in 2021.
- The last three Income towards Parent Company figures came in at -$235.7 million (Q4 2021), $170.5 million (Q3 2021), and -$77.6 million (Q2 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -235.70 Mn |
| Sep 28, 2021 | 170.46 Mn |
| Jun 30, 2021 | -77.62 Mn |
| Mar 31, 2021 | -60.97 Mn |
| Jun 30, 2020 | -44.27 Mn |
| Mar 31, 2020 | -30.28 Mn |
| Dec 31, 2019 | -37.75 Mn |
| Sep 30, 2019 | -34.24 Mn |
| Jun 30, 2019 | -99.44 Mn |
| Mar 31, 2019 | 33.60 Mn |
| Dec 31, 2018 | 22.09 Mn |
| Sep 30, 2018 | 12.78 Mn |
| Jun 30, 2018 | 70.12 Mn |
| Mar 31, 2018 | -22.31 Mn |
| Jun 30, 2016 | 29.56 Mn |
| Jun 30, 2015 | 23.49 Mn |